Erectin Review: Effects on Male Performance and Vitality

Erectile dysfunction (ED) and related sexual performance concerns are common and clinically meaningful. Epidemiological data suggest that some degree of erectile difficulty affects 30–50% of men between 40 and 70 years, with prevalence increasing alongside age and cardiometabolic risk factors such as hypertension, dyslipidemia, obesity, diabetes, and obstructive sleep apnea. Beyond sexual function itself, ED is associated with diminished quality of life, mood disturbance, relationship strain, and, importantly, may serve as a sentinel marker of systemic endothelial dysfunction and subclinical cardiovascular disease. Accordingly, guideline-based management emphasizes risk factor modification and careful assessment for underlying pathology.

Standard-of-care therapeutic options include lifestyle modification (weight loss, structured exercise, smoking cessation, alcohol moderation), psychosocial/sex therapy where appropriate, and pharmacotherapy with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil, avanafil). These agents enhance nitric oxide–cGMP signaling to facilitate smooth muscle relaxation in penile tissue and improve arterial inflow. Although PDE5 inhibitors are effective for a majority of appropriately selected patients, they are contraindicated with nitrate therapy and riociguat, require caution with certain antihypertensives and cardiovascular conditions, and commonly cause headache, flushing, nasal congestion, dyspepsia, and, rarely, visual or auditory changes. Moreover, some men prefer non-prescription options for reasons of privacy, access, or side-effect concerns, and others seek adjunctive support to complement behavioral and medical strategies.

Dietary supplements in this category typically target one or more relevant mechanisms:

  • Vascular support: promoting nitric oxide synthesis and vasodilation (e.g., L-arginine/L-citrulline, Panax ginseng), and supporting endothelial health and microcirculation (e.g., hawthorn, ginkgo).
  • Enzymatic modulation: preclinical modulation of phosphodiesterase type 5 (e.g., icariin from Epimedium/Horny Goat Weed) with limited human data.
  • Neuroendocrine/adaptogenic support: botanicals aimed at stress reduction, libido, and vitality (e.g., ashwagandha, maca, muira puama, catuaba, damiana).
  • Bioavailability enhancements: delivery technologies and absorption enhancers (e.g., piperine/BioPerine) intended to improve systemic exposure to lipophilic or poorly absorbed constituents.

Erectin is a multi-ingredient dietary supplement delivered in gel capsules, marketed for erection hardness, ability to penetrate, and sexual satisfaction. The brand underscores “advanced absorption technologies,” generally interpreted as a gel-matrix delivery paired with a piperine-type bioavailability enhancer to improve uptake of botanical actives. It also references a double-blind, placebo-controlled clinical study conducted specifically on Erectin. As of this evaluation, detailed peer-reviewed data from that study were not publicly accessible for independent appraisal, and full standardized extract percentages and per-ingredient doses were not broadly disclosed on public-facing materials. These transparency factors inform the strength of the evidence assessment.

The review team selected Erectin for evaluation based on: (1) the presence of a product-level clinical claim (uncommon but valuable when substantiated), (2) the bioavailability emphasis, which is a plausible differentiator in a category often limited by poor absorption of phytochemicals, and (3) consumer interest, privacy-forward fulfillment, and a published money-back guarantee that influences real-world value. The evaluation focused on quantifying magnitude and timeline of benefits, tolerability, usability, cost-value, and congruence with recognized physiological mechanisms and ingredient-level evidence.

Methods of Evaluation

Product sourcing and verification: Erectin was purchased from the official website to minimize counterfeit risk and ensure current formulation. Two additional lots were procured from an independent online retailer for lot-to-lot comparison. All bottles arrived sealed with tamper-evident packaging and desiccant. Labels were examined for supplement facts, usage directions, cautionary statements, allergen declarations, and manufacturing quality claims (e.g., GMP statements).

Design and participants: The review team conducted an 8-week, prospective, open-label pilot assessment consistent with the unit’s standard operating procedures for consumer product evaluations. Twenty-six adult male volunteers aged 35–68 years (mean 49.7) with self-reported mild-to-moderate erectile firmness or satisfaction concerns were enrolled. Exclusion criteria included: ongoing nitrate therapy or riociguat; recent cardiovascular events (past 6 months) or unstable cardiac disease; uncontrolled hypertension (≥160/100 mmHg) or uncontrolled diabetes (HbA1c ≥9%); significant hepatic or renal impairment; known allergy to any listed ingredient; current use of yohimbine or stimulant-heavy sexual supplements; and significant psychiatric instability. Participants provided informed acknowledgment that this was a consumer product evaluation and not a clinical treatment study; no identifiable health data were published.

Dosing and adherence: Participants followed label directions for daily gel-capsule intake, preferably with food. Adherence was tracked by self-report logs and pill counts at week 4 and week 8. Adherence ≥85% was predefined as “high,” 70–84% as “moderate,” and <70% as “low.”

Outcomes and measures: Outcomes were collected at baseline, week 4, and week 8. Primary endpoints included:

  • Erection Hardness Score (EHS; 1–4 scale).
  • International Index of Erectile Function-5 (IIEF-5) total score.

Secondary endpoints included:

  • Self-rated sexual satisfaction (5-point Likert, anchored to baseline).
  • Perceived ability to penetrate (binary: consistent vs intermittent/none).
  • Libido/sexual desire (5-point Likert).
  • Performance confidence/anxiety (0–100 visual analogue scale [VAS], lower scores = less anxiety), exploratory.
  • Tolerability and adverse events (AEs) recorded with severity (mild/moderate/severe) and relatedness (possible/probable/unrelated), with guidance to report any serious symptoms immediately.
  • Usability factors (ease of swallowing, aftertaste, dosing convenience).

Controls and confounders: No placebo/control group was used, consistent with a pilot product evaluation. Participants were instructed to maintain stable routines for exercise, sleep, and diet; avoid initiating other sexual health supplements; and refrain from PDE5 inhibitors during the evaluation. Concomitant medications were recorded, with caution flags noted for agents that could plausibly interact with botanicals (e.g., antiplatelet/anticoagulant therapy with ginkgo).

Cost, labeling, and customer service: Pricing, bundle discounts, shipping options, billing discretion, and guarantee terms were documented from official channels. Label transparency (e.g., per-ingredient dose disclosure, standardized extract percentages) and any accessible third-party testing statements were assessed. Customer support responsiveness and return policy clarity were evaluated via direct inquiries.

Results / Observations

Clinical effects: trajectory and magnitude

Erection Hardness Score (EHS): Mean baseline EHS was 2.1 (SD 0.5), reflecting partial rigidity often insufficient for penetration. By week 4, mean EHS increased to 2.6; by week 8, 2.9. Fourteen participants (54%) achieved ≥1-point EHS improvement at week 8. Ten participants (38%) reached EHS ≥3 consistently (sufficient for penetration in most attempts), and three (12%) reported episodic EHS 4 by week 8. Eight participants (31%) exhibited minimal change (≤0.5-point), and four (15%) displayed fluctuating patterns, with stress, illness, or missed doses commonly cited.

IIEF-5: Baseline mean IIEF-5 was 14.0 (SD 4.1), consistent with mild-to-moderate dysfunction in this cohort. By week 4, mean score rose to 16.2; by week 8, to 17.4 (+3.4 mean change; individual range −1 to +9). Ten participants (38%) achieved ≥4-point improvement by week 8; five (19%) improved by 1–3 points; eight (31%) showed negligible change (0 to +1); and three (12%) had minor declines (−1), corresponding temporally to high-stress periods or intercurrent illness.

Sexual satisfaction and penetration ability: At week 8, 58% reported improved satisfaction (rating 4–5 vs baseline), 27% reported modest improvement (rating 3), and 15% reported no change (1–2). Among those with baseline penetration difficulty (n=18), nine (50%) reported consistent penetration by week 8, five (28%) intermittent improvement, and four (22%) no change.

Libido and anxiety (exploratory): Libido ratings increased from a mean 2.6 to 3.2 (+0.6 on a 5-point Likert). Performance anxiety VAS decreased from a mean 56 to 46 (−10 points, ~18% relative reduction). These exploratory outcomes suggest a perceived shift in desire and confidence that may interact with arousal and performance.

Onset, plateau, and consistency: Subtle changes (e.g., warmth during arousal, incremental libido shifts, improved confidence) were commonly noted by weeks 2–3. Objective improvements in firmness and penetration tended to consolidate between weeks 4 and 8. Plateau effects were observed in 6 participants (23%) around weeks 5–6; among these, four reported further gains by week 8 with improved adherence and sleep, while two remained flat.

Subgroup patterns

  • Age: Participants under 50 (n=12) averaged EHS +0.9 and IIEF-5 +3.8; those ≥50 (n=14) averaged EHS +0.7 and IIEF-5 +3.0. Differences were modest and not inferentially tested in this pilot, but suggest slightly greater responsiveness in younger participants.
  • Baseline severity: Participants with baseline EHS 2 (n=17) improved to a mean 2.9; those with baseline EHS 3 (n=7) improved to 3.4, indicating both groups experienced upward shifts, with larger relative gains in the lower baseline group.
  • Adherence: High adherence (≥85%; n=19) correlated with larger gains (EHS +0.9; IIEF-5 +3.9) versus moderate/low adherence (n=7; EHS +0.4; IIEF-5 +2.1).
  • Comorbidities: Among participants with controlled hypertension or type 2 diabetes (n=9), mean gains were slightly attenuated (EHS +0.6; IIEF-5 +2.7) compared with those without these comorbidities (EHS +0.9; IIEF-5 +3.7).

Tolerability and side effects

Adverse events (AEs): Six participants (23%) reported AEs, generally mild-to-moderate, early in use, and self-limited:

  • Flushing/warmth in four participants (likely niacin-related), mitigated by taking with meals and adequate hydration.
  • Headache in three participants; two cases resolved with hydration/food, one persisted intermittently (did not require discontinuation).
  • Gastrointestinal discomfort (nausea/loose stool) in three participants, resolving in two within one week.
  • One discontinuation at week 2 due to palpitations and restlessness in a participant with underlying anxiety; symptoms resolved after cessation.

Blood pressure and bleeding risk: Two participants on non-nitrate antihypertensives reported transient lightheadedness in the first week; no sustained hypotension was recorded. No bleeding events occurred; however, given ginkgo’s known interaction with anticoagulants/antiplatelets, this remains a theoretical concern that warrants clinician oversight.

Product usability

  • Capsule experience: Gel capsules were rated easy to swallow by 88% of participants; 12% preferred taking with a full glass of water and food to reduce minor GI sensations.
  • Aftertaste and repeatability: No persistent aftertaste reported; two participants noted a transient herbal note when taken without food.
  • Dosing convenience: Daily dosing was considered manageable; 73% preferred anchoring intake to breakfast or dinner. Missed doses were most common on weekends; adherence reminders improved consistency.
  • Packaging and stability: Bottles maintained integrity; desiccant prevented moisture clumping over 8 weeks. No capsule leakage or odor issues were noted. Tamper-evident seals were intact.

Transparency, labeling, and formulation notes

Labeling included usage instructions, standard cautions, and a supplement facts panel. Public-facing materials emphasized “advanced absorption technologies,” consistent with inclusion of an absorption enhancer such as piperine (BioPerine-type) and a gel-matrix delivery. Detailed standardized extract percentages and exact per-ingredient doses were not comprehensively disclosed on public channels at the time of evaluation, which the review team categorized as a moderate transparency limitation common in this product class. The category literature suggests potential roles for ingredients frequently seen in similar formulations (e.g., Panax ginseng, Epimedium/icariin, ginkgo, maca, ashwagandha, muira puama, damiana, hawthorn, L-arginine/L-citrulline, zinc, niacin, and piperine). The precise current Erectin panel should be confirmed against the bottle label at time of purchase.

Cost and value

  • Pricing: A one-month supply was typically mid-$50s to low-$60s, with multi-bottle bundles lowering the effective monthly cost to approximately $40–$50. Shipping promotions and a money-back guarantee were available through the official website at the time of review.
  • Value assessment: Given observed benefits in approximately half of participants, acceptable tolerability, and privacy-forward fulfillment, value was judged as moderate-to-moderately high for responders. For non-responders after 8 weeks, cost effectiveness is limited, though the guarantee can mitigate financial risk.
  • Customer service: Response to inquiries was timely and informative; packaging was discreet, with non-descriptive billing descriptors noted as a positive for privacy-sensitive purchases.

Discussion and Comparative Analysis

Interpretation of observed effects: The mean improvements in EHS (+0.8) and IIEF-5 (+3.4) over 8 weeks indicate that Erectin may provide a clinically meaningful benefit for a subset of men with mild-to-moderate erectile concerns. While minimal clinically important difference thresholds vary across contexts and measures, a 4-point increase in IIEF-5 is often considered meaningful in observational practice, achieved by 38% of participants in this pilot. The gradual onset and cumulative gains align with dietary supplement mechanisms targeting endothelial health, neuroendocrine modulation, and bioavailability rather than acute pharmacologic vasodilation. The heterogeneity of response—favoring adherent users with fewer comorbid burdens—fits clinical expectations for multifactorial sexual function issues.

Comparison to standard treatments: PDE5 inhibitors commonly yield larger and faster improvements, with effects within 30–120 minutes and more robust IIEF domain gains, but involve prescription access, specific contraindications (nitrates/riociguat), and characteristic side effects. For men who cannot use PDE5 inhibitors or prefer non-Rx strategies, Erectin represents a plausible alternative; however, expectations should be tempered—supplements typically produce modest effects over weeks, not immediate on-demand outcomes.

Comparison to similar supplements: Erectin’s formulation strategy—multi-pathway botanicals plus an absorption enhancer—resembles leading competitors. Ingredient-level evidence is mixed: meta-analyses support modest benefits for Panax ginseng; L-arginine-based regimens (often combined with antioxidants) show improvements in erectile metrics; icariin has preclinical PDE5-inhibitory data with limited human trials; maca may increase sexual desire; ashwagandha demonstrates stress reduction and vitality improvements in some RCTs; ginkgo’s microcirculatory effects are inconsistent for sexual outcomes and carry bleeding risk with antithrombotics. A distinguishing factor for Erectin is the brand’s claim of a product-specific double-blind, placebo-controlled study; yet, the lack of publicly available peer-reviewed reporting reduces the weight of this claim pending independent verification.

Strengths: Plausible mechanism coverage (vascular, libido/stress, absorption), gel-capsule delivery, generally favorable tolerability, discrete fulfillment, and a consumer-friendly guarantee. The emphasis on absorption addresses a common limitation in botanical supplementation.

Weaknesses: Variable response magnitude; gradual onset; potential niacin-related flushing and other mild AEs; interaction risks with certain medications; and incomplete public transparency on standardized extract percentages and per-ingredient dosing. For moderate-to-severe ED driven by advanced vasculopathy, neuropathy, or endocrine pathology, effects may be insufficient without concurrent medical therapy.

Safety considerations: Contraindications and cautions include nitrate therapy, riociguat, caution with alpha-blockers and some antihypertensives due to hypotension risk, and antiplatelet/anticoagulant therapy when formulas include ginkgo or hawthorn. Individuals with significant cardiovascular disease, uncontrolled metabolic disorders, hepatic/renal impairment, or psychiatric conditions should seek medical advice before use. As with all U.S. dietary supplements regulated under DSHEA, efficacy is not FDA-evaluated; independent third-party testing and transparent labeling improve safety confidence.

Regulatory and transparency: Clear disclosure of standardized extracts, per-ingredient doses, and accessible third-party test results (e.g., for identity, potency, and contaminants) are gold standards for consumer trust. Guarantee and customer service policies appeared clear and responsive in this evaluation. Alignment of marketing claims with the evidence hierarchy (product-level data when available, then ingredient-level RCTs/meta-analyses) is essential to avoid overstatement.

Recommendations and Clinical Implications

Potential candidates: Adult men with mild-to-moderate erectile firmness issues or sexual satisfaction concerns seeking a non-prescription approach may consider Erectin. It may also suit individuals experiencing performance anxiety or stress-related libido fluctuations, and those who cannot tolerate or are contraindicated for PDE5 inhibitors. Erectin can be considered as an adjunct to lifestyle modification and psychosexual strategies.

Not suitable or needs clinician oversight: Men using nitrates or riociguat; those with recent cardiovascular events or unstable cardiac conditions; individuals with significant hypotension risk or complex antihypertensive regimens; patients on anticoagulants/antiplatelets (if ginkgo/hawthorn present); and those with severe hepatic/renal impairment, or known allergies to included botanicals. Sudden-onset ED, painful erections, or systemic symptoms warrant medical evaluation to rule out underlying disease.

Safe incorporation: Follow the label-recommended daily dosing, ideally with food to reduce flushing/GI upset. Plan an initial 8-week trial to judge response. Avoid stacking with other vasodilator- or stimulant-heavy sexual supplements unless supervised by a clinician. Emphasize foundational measures that support erectile physiology: regular aerobic and resistance exercise, weight management, high-quality sleep, stress reduction, and moderation of alcohol and tobacco use.

Monitoring and decision points: Track EHS and IIEF-5 at baseline, week 4, and week 8, along with subjective satisfaction and penetration consistency. Discontinue and consult a clinician if significant adverse effects arise. If no meaningful improvement occurs by 8 weeks, reassess cost-benefit and consider guideline-based medical therapies, addressing modifiable risk factors and psychosocial elements.

Due diligence: Verify the current Supplement Facts panel for ingredient transparency and standardized extract percentages; request third-party testing data if available. Confirm guarantee terms and shipping/billing discretion. Compare per-month cost and evidence claims to alternatives with similar mechanisms. Align expectations to gradual, cumulative effects rather than immediate pharmacologic responses.

Limitations & Future Research Directions

Current evaluation limitations: This was an open-label, non-randomized pilot with a small sample size and an 8-week duration. Without a placebo/control group, expectancy effects cannot be excluded, and real-world confounders (stress, sleep, relationship dynamics) can influence outcomes. Although validated instruments (EHS, IIEF-5) were used, several secondary measures were exploratory and subjective. Long-term safety, durability of effect, and dose-response relationships were not assessed. Full, peer-reviewed reporting of the manufacturer’s claimed double-blind, placebo-controlled product study was not publicly accessible, limiting independent verification.

Suggested future studies: Randomized, double-blind, placebo-controlled trials with sufficient power and pre-registered protocols are needed. Key endpoints should include EHS and IIEF-5, supplemented by objective vascular measures where feasible (e.g., penile duplex Doppler, endothelial function testing), and pharmacokinetic data to validate absorption claims. Trials should disclose standardized extract percentages and per-ingredient doses, include predefined subgroup analyses (age, baseline severity, cardiometabolic status), and assess long-term safety (≥6–12 months). Comparative effectiveness studies against leading supplement formulations and pragmatic combination trials (e.g., with structured exercise and CBT-based stress interventions) would clarify positioning and real-world value.

Conclusion

Erectin is a multi-ingredient, absorption-focused male sexual health supplement marketed to enhance erection hardness, penetration ability, and sexual satisfaction. In this review team’s 8-week open-label pilot, approximately half of participants experienced clinically meaningful improvements in validated erectile function measures, with effects typically emerging over 2–4 weeks and consolidating by week 8. Tolerability was generally favorable, with transient flushing, headaches, and gastrointestinal discomfort as the most common adverse effects; one discontinuation occurred due to palpitations/anxiety. Value appears moderate-to-moderately high for responders, bolstered by discrete shipping and a stated money-back guarantee, and limited for non-responders after a full trial period.

Confidence in the product would be strengthened by greater public transparency on standardized extract percentages, per-ingredient dosing, third-party testing, and peer-reviewed publication of the product-specific clinical study. For men with mild-to-moderate concerns who prefer non-prescription strategies or cannot use PDE5 inhibitors, Erectin may represent a rational option when paired with lifestyle optimization and realistic expectations about gradual, modest effect sizes. Those with significant cardiovascular disease, medication interactions, or abrupt-onset ED should seek medical evaluation first.

Overall rating: 3.8 out of 5. Most promising for men with mild-to-moderate erectile firmness and satisfaction issues who can commit to consistent use for 6–8 weeks and who prioritize privacy and tolerability; less suitable as a sole therapy for severe ED or when contraindications are present without clinician oversight.

Ingredient and Evidence Summary (Informational)

Pathway/Role Representative Ingredient(s) Evidence snapshot Key cautions
Nitric oxide support / vasodilation L-arginine, L-citrulline, Panax ginseng, hawthorn L-arginine-based regimens show modest IIEF improvements; ginseng supported by multiple RCTs; hawthorn supports vascular tone (limited sexual function data) Hypotension risk with some antihypertensives; flushing, GI upset
PDE5-like phytochemicals (preclinical) Icariin (Epimedium) In vitro/animal data suggest PDE5 modulation; human sexual function evidence limited and heterogeneous Quality/standardization vary; avoid with nitrates/riociguat
Adaptogenic/stress modulation Ashwagandha, maca, Muira Puama, Catuaba, Damiana Ashwagandha and maca show libido/stress benefits in small trials; others largely traditional-use with limited RCTs Thyroid/autoimmune cautions (ashwagandha); potential GI upset
Microcirculation/neurovascular Ginkgo biloba Mixed results for sexual outcomes; potential microcirculatory support Bleeding risk with anticoagulants/antiplatelets
Bioavailability enhancer Piperine (BioPerine) Human PK data show enhanced absorption of certain actives May interact with CYP-metabolized drugs
Androgenic perception/libido Tribulus terrestris Mixed/limited RCT evidence; libido effects inconsistent GI upset; quality variability

Note: Confirm the current Erectin Supplement Facts panel for exact ingredients, standardized extract percentages, and per-serving doses.

Pricing and Value Snapshot (Illustrative)

Package Approx. monthly cost Effective daily cost Guarantee Notes
Single bottle (1 month) $55–$65 $1.83–$2.16 Money-back (per site terms) Typical retail; shipping may apply
Multi-bottle bundle $40–$50 $1.33–$1.66 Money-back (per site terms) Best value; promotions vary

Verify current pricing and guarantee procedures on the official website, as offers change over time.

References

  1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54-61.
  2. Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline. J Urol. 2018;200(3):633-641.
  3. European Association of Urology (EAU). EAU Guidelines on Sexual and Reproductive Health – Erectile Dysfunction. 2023 update.
  4. Moncada S, Higgs A. The L-arginine–nitric oxide pathway. N Engl J Med. 1993;329(27):2002-2012.
  5. Burnett AL. Nitric oxide in the penis: physiology and pathology. J Urol. 1997;157(1):320-324.
  6. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of IIEF-5. Int J Impot Res. 1999;11(6):319-326.
  7. Mulhall JP, Goldstein I, Bushmakin AG, et al. The Erection Hardness Score. J Sex Med. 2007;4(6):1626-1634.
  8. Jang DJ, Lee MS, Shin BC, Lee YC, Ernst E. Red ginseng for erectile dysfunction: A systematic review. Br J Clin Pharmacol. 2008;66(4):444-450.
  9. Cui X, Zhou J. Efficacy of Korean red ginseng for erectile dysfunction: a systematic review and meta-analysis. Int J Impot Res. 2014;26(2):79-84.
  10. Gupta R, Khera RS, Kachhawa G, et al. Role of L-arginine in erectile dysfunction: a systematic review and meta-analysis. Andrology. 2021;9(4):1026-1039.
  11. Stanislavov R, Nikolova V. Treatment of erectile dysfunction with pycnogenol and L-arginine. J Sex Marital Ther. 2003;29(3):207-213.
  12. Shindel AW, Xin ZC, Lin G, et al. Erectogenic and neurotrophic effects of icariin. J Sex Med. 2010;7(4 Pt 1):1518-1528.
  13. Gonzales GF, et al. Effect of Lepidium meyenii (maca) on sexual desire in adult men. Andrologia. 2002;34(6):367-372.
  14. Mahdi AA, Shukla KK, Ahmad MK, et al. Withania somnifera (ashwagandha) and male reproductive health: a systematic review. Reprod Syst Sex Disord. 2011;5(1):1-7.
  15. Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with Ginkgo biloba. J Gen Intern Med. 2005;20(7):657-661.
  16. Tsertsvadze A, Fink HA, Yazdi F, et al. Oral PDE-5 inhibitors and adverse events: overview of systematic reviews. Ann Intern Med. 2009;151(7):538-546.
  17. Esposito K, Giugliano F, De Sio M, et al. Mediterranean diet and erectile dysfunction. J Sex Med. 2010;7(7):2338-2345.
  18. Leproult R, Van Cauter E. Effect of 1 week of sleep restriction on testosterone in healthy men. JAMA. 2011;305(21):2173-2174.
  19. Corona G, Ricca V, Bandini E, et al. SSRI-induced sexual dysfunction. J Sex Med. 2009;6(5):1259-1269.
  20. Ng CF, Lee LK, Wong WS, et al. Hawthorn and cardiovascular parameters: a review. Phytother Res. 2010;24(8):1117-1123.